Applied Genetic Technologies Logo
AGTC to Present at Cell & Gene Meeting on the Mediterranean
April 14, 2022 08:00 ET | Applied Genetic Technologies Corporation
GAINESVILLE, Fla. and CAMBRIDGE, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development...
Applied Genetic Technologies Logo
AGTC to Showcase Interim Findings from Ongoing XLRP and Achromatopsia Phase 1/2 Trials at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting
April 04, 2022 16:45 ET | Applied Genetic Technologies Corporation
GAINESVILLE, Fla., and CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation¬†(Nasdaq: AGTC), a clinical stage biotechnology company focused on the...
Applied Genetic Technologies Logo
AGTC Announces Pricing of Public Offering of Common Stock
March 22, 2022 08:45 ET | Applied Genetic Technologies Corporation
GAINESVILLE, Fla., and CAMBRIDGE, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development...
Applied Genetic Technologies Logo
AGTC Announces Proposed Public Offering of Common Stock
March 21, 2022 16:01 ET | Applied Genetic Technologies Corporation
GAINESVILLE, Fla. and CAMBRIDGE, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development...
Applied Genetic Technologies Logo
AGTC to Participate in Upcoming Investor Conferences
March 08, 2022 16:05 ET | Applied Genetic Technologies Corporation
GAINESVILLE, Fla. and CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development...
Applied Genetic Technologies Logo
AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2021
February 14, 2022 07:00 ET | Applied Genetic Technologies Corporation
-Company on track to provide 3-month interim SKYLINE trial results in 2Q 2022- -Company to host management update and webcast today at 8:00 a.m. ET- GAINESVILLE, Fla. and CAMBRIDGE, Mass.,...
Applied Genetic Technologies Logo
AGTC Announces Robust Improvements in Visual Sensitivity in Adult and Pediatric Patients, and Plans to Continue Clinical Development of AGTC-401 in Patients with CNGB3 Achromatopsia
February 08, 2022 07:00 ET | Applied Genetic Technologies Corporation
AGTC-401 demonstrated a favorable safety profile through second-highest dose (1.1E+12 vg/mL) in ACHMB3 pediatric patientsAt the dose of 1.1E+12 vg/mL greater than 50% of the combined adults and...
Applied Genetic Technologies Logo
AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 14, 2022
February 07, 2022 08:00 ET | Applied Genetic Technologies Corporation
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development...
Applied Genetic Technologies Logo
AGTC Exceeds Enrollment Target in SKYLINE Trial of AGTC-501 for the Treatment of X-linked Retinitis Pigmentosa (XLRP)
January 11, 2022 08:00 ET | Applied Genetic Technologies Corporation
Company on track to report three-month interim study results, including visual acuity, visual sensitivity, mobility and safety data, in Q2 2022Company providing further updated guidance on other...
Applied Genetic Technologies Logo
AGTC to Participate in the H.C. Wainwright BioConnect 2022 Conference
January 04, 2022 08:00 ET | Applied Genetic Technologies Corporation
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development...